| How we treat patients with metastatic HER2-positive breast cancer G Nader-Marta, D Martins-Branco, E de Azambuja ESMO open 7 (1), 100343, 2022 | 78 | 2022 |
| Cisplatin versus carboplatin in combination with third‐generation drugs for advanced non‐small cell lung cancer V Vasconcellos, GN Marta, EMK Silva, AFT Gois, TB de Castria, R Riera Cochrane Database Syst Rev 2020 (1), CD009256, 2020 | 74 | 2020 |
| Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer E Agostinetto, A Losurdo, G Nader-Marta, A Santoro, K Punie, R Barroso, ... Expert opinion on investigational drugs 31 (6), 567-591, 2022 | 61 | 2022 |
| Prognostic value of HER2-low status in breast cancer: a systematic review and meta-analysis C Molinelli, F Jacobs, E Agostinetto, G Nader-Marta, M Ceppi, ... ESMO open 8 (4), 101592, 2023 | 43 | 2023 |
| A phase 2 study of first‐line nivolumab in patients with locally advanced or metastatic cutaneous squamous‐cell carcinoma RR Munhoz, G Nader‐Marta, VP de Camargo, MM Queiroz, ... Cancer 128 (24), 4223-4231, 2022 | 31 | 2022 |
| CDK4/6 and PI3K inhibitors: a new promise for patients with HER2‐positive breast cancer E Agostinetto, V Debien, GN Marta, M Lambertini, M Piccart‐Gebhart, ... European journal of clinical investigation 51 (7), e13535, 2021 | 25 | 2021 |
| Trends in melanoma mortality in Brazil: a registry-based study G Nader Marta, RR Munhoz, MLP Teixeira, BC Waldvogel, ... JCO global oncology 6, 1766-1771, 2020 | 24 | 2020 |
| Immune thrombocytopenia and autoimmune thyroid disease: a controversial overlap GN Marta, FPF de Campos Autopsy & Case Reports 5 (2), 45, 2015 | 23 | 2015 |
| Efficacy of tyrosine kinase inhibitors for the treatment of patients with HER2-positive breast cancer with brain metastases: a systematic review and meta-analysis G Nader-Marta, D Martins-Branco, E Agostinetto, M Bruzzone, M Ceppi, ... ESMO open 7 (3), 100501, 2022 | 21 | 2022 |
| Outcomes and prognostic factors in a large cohort of hospitalized cancer patients with COVID-19 G Nader Marta, R Colombo Bonadio, O Nicole Encinas Sejas, G Watarai, ... JCO Global Oncology 7, 1084-1092, 2021 | 21 | 2021 |
| Treatment priorities in oncology: do we want to live longer or better? GN Marta, LG Del Nero, GN Marta, A Mangabeira, G Critchi, MJ Kovacs, ... Clinics 69 (8), 509-514, 2014 | 18 | 2014 |
| ROSALINE: a phase II, neoadjuvant study targeting ROS1 in combination with endocrine therapy in invasive lobular carcinoma of the breast E Agostinetto, G Nader-Marta, M Paesmans, L Ameye, I Veys, L Buisseret, ... Future Oncology 18 (22), 2383-2392, 2022 | 16 | 2022 |
| Antibody–drug conjugates: the evolving field of targeted chemotherapy for breast cancer treatment G Nader-Marta, C Molinelli, V Debien, D Martins-Branco, P Aftimos, ... Therapeutic advances in medical oncology 15, 17588359231183679, 2023 | 15 | 2023 |
| Prognostic value of systemic inflammatory biomarkers in patients with metastatic renal cell carcinoma G Nader Marta, P Isaacsson Velho, RRC Bonadio, M Nardo, SF Faraj, ... Pathology & Oncology Research 26, 2489-2497, 2020 | 14 | 2020 |
| Cystic brain metastases in ALK-rearranged non-small cell lung cancer GN Marta, RRCC Bonadio, RE Martins, HB Zuppani, J Gilberto de Castro ecancermedicalscience 12, 818, 2018 | 13 | 2018 |
| Circulating tumor DNA for predicting recurrence in patients with operable breast cancer: a systematic review and meta-analysis G Nader-Marta, M Monteforte, E Agostinetto, M Cinquini, ... ESMO open 9 (3), 102390, 2024 | 11 | 2024 |
| Immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer: a systematic review and meta-analysis D Martins-Branco, G Nader-Marta, A Tecic Vuger, V Debien, L Ameye, ... Journal of cancer research and clinical oncology 149 (7), 3075-3080, 2023 | 10 | 2023 |
| Efficacy and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma GN Marta, LG da Fonseca, MI Braghiroli, F Moura, PM Hoff, J Sabbaga Clinics 76, e2498, 2021 | 9 | 2021 |
| 1689O Comprehensive mapping review of real-world evidence publications focusing on targeted therapies in solid tumors: a collaborative work from ESMO real-world data and … A Pellat, T Grinda, A Prelaj, P Cresta, A Valachis, I Zerdes, DM Branco, ... Annals of Oncology 34, S925, 2023 | 8 | 2023 |
| CA209-9JC: A phase II study of first-line nivolumab (NIVO) in patients (pts) with locally advanced or metastatic cutaneous squamous cell carcinoma. RR Munhoz, VPD Camargo, GN Marta, JC Martins, M Nardo, CC Barbosa, ... Journal of Clinical Oncology 38 (15_suppl), 10044-10044, 2020 | 8 | 2020 |
